Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?
Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?
复制标题
DOI：
10.21037/atm.2018.10.35
复制
发表时间：
2018-10
影响因子：
--
通讯作者：
K. Smith-Jackson;K. Marchbank
中科院分区：
文献类型：
--
作者：
K. Smith-Jackson;K. Marchbank
在某些补体介导的疾病和疾病状态中，仍然迫切需要更好的抗补体药物(1)。上田等人最近公布的数据。(2)似乎为非典型溶血性尿毒症综合征(AHUS)的靶向补体激活提供了另一种高效的解决方案。
The need for better anti-complement drugs in certain complement mediated diseases and disease states remains pressing (1). The recent data published by Ueda et al. (2), appears to offer another highly effective solution to target complement activation in atypical haemolytic uraemic syndrome (aHUS).